All In Biotech

Drug Trial Radar · NCT07593924

Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Administered as a Series of 2 Infant Doses and 1 Toddler Dose in Healthy Infants

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.

Conditions

  • Pneumococcal Infectious Diseases

Interventions

  • Sinovac PCV13Biological

    One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.

  • Prevenar 13™Biological

    One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .Time frame: 30 days after dose 2.
  2. Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.Time frame: 30 days after dose 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences

    Imus, Cavite, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.